Fig. 3
From: Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model
Therapeutic effects of drug delivery formulations in mice with dextran sulfate sodium-induced colitis. a The methods for DSS-induced colitis and oral delivery carriers with infliximab (IFX) administration, control (n = 4), DSS only (n = 10), IFX-L group (n = 6), AC-IFX-L (n = 6), EAC-IFX-L (n = 10), PO-IFX (n = 8). b Body weight changes of each group in DSS-induced colitis mouse model. c Colon length; values are represented as length (cm). d The clinical activity scores in the control group and treatment groups measured using the disease activity index (DAI). e Histopathologic features of nanocomposite carriers and IFX delivery formulations on the DSS-induced colitis mouse model, via PAS staining. Arrows indicate inflammatory cells in the lamina propria. Scale bar: 20 μm. Histomorphological scores and Goblet cell scores. Data are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Statistical significance was assessed using Student’s t-test (d) and one-way ANOVA followed by Dunnett post-test